<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><?origin nihpa?><?iso-abbr Leukemia?><?submitter-system nihms?><?submitter-canonical-name Nature Publishing Group?><?submitter-canonical-id NATURE-STRUCTUR?><?submitter-userid 8068858?><?submitter-authority myNCBI?><?submitter-login nature-structure?><?submitter-name Nature Publishing Group?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8704895</journal-id><journal-id journal-id-type="pubmed-jr-id">5536</journal-id><journal-id journal-id-type="nlm-ta">Leukemia</journal-id><journal-id journal-id-type="iso-abbrev">Leukemia</journal-id><journal-title-group><journal-title>Leukemia</journal-title></journal-title-group><issn pub-type="ppub">0887-6924</issn><issn pub-type="epub">1476-5551</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">5986278</article-id><article-id pub-id-type="pmid">28280276</article-id><article-id pub-id-type="doi">10.1038/leu.2017.80</article-id><article-id pub-id-type="manuscript">nihpa855382</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Regulation of PI3K signaling in T cell acute lymphoblastic leukemia:
a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for
PIK3CD</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Tian</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yaling</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jiayu</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Wenhui</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Wuping</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mi</surname><given-names>Yingchang</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Goswami</surname><given-names>Rashmi S.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>You</surname><given-names>Jeffrey Q.</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>M. Diana</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Calin</surname><given-names>Steliana</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Miranda</surname><given-names>Roberto N.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Calin</surname><given-names>George A.</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Xiaoyan</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Zweidler-McKay</surname><given-names>Patrick A.</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><name><surname>Weng</surname><given-names>Andrew P.</given-names></name><xref ref-type="aff" rid="A14">14</xref></contrib><contrib contrib-type="author"><name><surname>Medeiros</surname><given-names>L. Jeffrey</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yizhuo</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>You</surname><given-names>M. James</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A15">15</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib></contrib-group><aff id="A1">
<label>1</label>Department of Hematopathology, the University of Texas MD Anderson
Cancer Center, Houston, TX, USA</aff><aff id="A2">
<label>2</label>Department of Hematology, Tianjin Medical University Cancer
Institute and Hospital, Tianjin, China</aff><aff id="A3">
<label>3</label>Shaoxing University Medical School, Shaoxing City, Zhejiang
Province, China</aff><aff id="A4">
<label>4</label>Department of Laboratory Medicine, Harbin Medical University Tumor
Hospital, Heilongjiang Province, China</aff><aff id="A5">
<label>5</label>Department of Leukemia, Institute of Hematology and Blood Disease
Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
Tianjin, China</aff><aff id="A6">
<label>6</label>Department of Laboratory Medicine and Pathobiology, Faculty of
Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada</aff><aff id="A7">
<label>7</label>Department of Molecular and Cellular Oncology, the University of
Texas MD Anderson Cancer Center, Houston, TX, USA</aff><aff id="A8">
<label>8</label>Department of Immunology, the University of Texas MD Anderson Cancer
Center, Houston, TX, USA</aff><aff id="A9">
<label>9</label>Department of Experimental Therapeutics and Center for RNA
Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center,
Houston, TX, USA</aff><aff id="A10">
<label>10</label>Department of Pathology, Shanghai Cancer Center, Fudan University,
Shanghai, China</aff><aff id="A11">
<label>11</label>Department of Experimental Radiation Oncology, the University of
Texas MD Anderson Cancer Center, Houston, TX, USA</aff><aff id="A12">
<label>12</label>Division of Pediatric, the University of Texas MD Anderson Cancer
Center, Houston, TX, USA</aff><aff id="A13">
<label>13</label>Department of Genetics, the University of Texas MD Anderson Cancer
Center, Houston, TX, USA</aff><aff id="A14">
<label>14</label>Department of Pathology &amp; Laboratory Medicine, the University
of British Columbia, Vancouver, BC, Canada</aff><aff id="A15">
<label>15</label>The University of Texas Graduate School of Biomedical Sciences at
Houston, Houston, TX, USA</aff><author-notes><corresp id="FN1">Corresponding author: M. James You, Department of Hematopathology,
Unit 72, The University of Texas MD Anderson Cancer Center, 1515 Holcombe
Boulevard, Houston, TX, USA, 77030. Tel: +1(713) 745-1657. Fax:
+1(713) 792-7273. <email>mjamesyou@mdanderson.org</email>. Yizhuo Zhang,
Department of Hematology, Tianjin Medical University Cancer Institute and
Hospital, Huanhuxi Road, Tianjin, China, 300000. Tel: +8618622221239.
Fax: +862226690818. <email>yizhuozhang111@163.com</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>17</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>6</month><year>2018</year></pub-date><volume>31</volume><issue>11</issue><fpage>2355</fpage><lpage>2364</lpage><!--elocation-id from pubmed: 10.1038/leu.2017.80--><permissions><license><license-p>Users may view, print, copy, and download text and data-mine the
content in such documents, for the purposes of academic research, subject
always to the full Conditions of use: <uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p></license></permissions><abstract><p id="P1">T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic
malignancy, and T-ALL patients are prone to early disease relapse and suffer
from poor outcomes. The PTEN, PI3K/AKT, and Notch pathways are frequently
altered in T-ALL. PTEN is a tumor suppressor that inactivates the PI3K pathway.
We profiled miRNAs in <italic>Pten</italic>-deficient mouse T-ALL and identified
miR-26b as a potentially dysregulated gene. We validated decreased expression
levels of miR-26b in mouse and human T-ALL cells. In addition, expression of
exogenous miR-26b reduced proliferation and promoted apoptosis of T-ALL cells
<italic>in vitro</italic>, and hindered progression of T-ALL <italic>in
vivo</italic>. Furthermore, miR-26b inhibited the PI3K/AKT pathway by
directly targeting <italic>PIK3CD</italic>, the gene encoding PI3K&#948;, in
human T-ALL cell lines. ShRNA for <italic>PIK3CD</italic> and CAL-101, a PIK3CD
inhibitor, reduced the growth and increased apoptosis of T-ALL cells. Finally,
we showed that PTEN induced miR-26b expression by regulating the differential
expression of Ikaros isoforms that are transcriptional regulators of miR-26b.
These results suggest that miR-26b functions as a tumor suppressor in the
development of T-ALL. Further characterization of targets and regulators of
miR-26b may be promising for the development of novel therapies.</p></abstract><kwd-group><kwd>miR-26b</kwd><kwd>T-ALL</kwd><kwd>PTEN</kwd><kwd>Ikaros</kwd><kwd>PI3K/AKT</kwd><kwd>PIK3CD</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p id="P2">T-cell acute lymphoblastic leukemia (T-ALL) is a clinically aggressive
hematologic malignancy that accounts for 15% of pediatric and 25% of
adult ALL cases.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Limited targeting
therapies are available for patients with T-ALL because of an insufficient
understanding of T-ALL genetics and biology. Despite current therapies, including
chemotherapy and bone marrow transplant, 25&#8211;50% of T-ALL patients
relapse, resulting in a poor outcome with a 5-year overall survival rate of
approximately 45%.<sup><xref rid="R2" ref-type="bibr">2</xref>&#8211;<xref rid="R4" ref-type="bibr">4</xref></sup></p><p id="P3">Class I phosphoinositide-3 kinases (PI3Ks) are a group of signaling
transduction enzymes involved in the production of intracellular second messenger
lipid signals. The class I PI3Ks are sub-divided into two groups based on their
structures: class IA PI3Ks are heterodimers consisting of one regulatory subunit and
one catalytic subunit (p110&#945;, p110&#946;, or p110&#948;). Unlike
p110&#945; and p110&#946;, which are ubiquitously expressed, p110&#948; is
highly enriched in leukocytes. PI3K p110&#948; (PI3K&#948;) is encoded by
<italic>PIK3CD</italic>. The PI3K pathway is activatedin 92% of T-ALL
cell lines and 81% of primary T-ALL samples, respectively.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> PTEN, a tumor suppressor, is the
most important negative regulator of the PI3K signaling pathway. In addition to its
canonical, PI3K inhibition-dependent functions, PTEN also can function as a tumor
suppressor in a PI3K-independent manner. PTEN loss of function due to gene mutations
or deletions occurs in 22% of T-ALL patients, leading to hyperactivation of
PI3K and its downstreamAKT signaling pathway.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p><p id="P4">Ikaros is a zinc finger transcriptional factor encoded by
<italic>IKZF1</italic> and is a key regulator and tumor suppressor in
hematopoiesis.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Loss of
Ikaros function is common in human T-ALL.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Ikaros isoforms share a common structure of two functional
domains composed of zinc-fingers. The first four zinc-fingers represent a
DNA-binding domain (DBD) whereas the last two zinc-fingers are components of a
dimerization domain; the latter allows competitive binding between
isoforms.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> These domains
are encoded by seven different exons, and differential splicing generates different
isoforms. Ikaros isoforms that display at least three zinc-fingers in the DBD are
considered dominant positive (DP, IK1-3), whereas Ikaros isoforms with less than
three zinc-fingers in the DBD are considered dominant negative (DN, IK4-9). DN
isoforms are not only defective typically due to decreased/no DNA binding capacity
but also may interfere with the activity of functional isoforms. Mice with the
heterozygous loss of Ikaros rapidly develop T-cell leukemia.<sup><xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref></sup></p><p id="P5">microRNAs (miRs) are short noncoding RNAs of 20&#8211;22 nucleotides that
function to regulate gene expression at the posttranscriptional level. miRs play
fundamental roles in the regulation of cellular proliferation, differentiation, and
apoptosis. miRs are dysregulated in many types of cancer, including T-ALL. miRs can
function as oncogenes, favoring the initiation and progression of cancers, or as
tumor suppressors, preventing tumorigenesis.<sup><xref rid="R11" ref-type="bibr">11</xref>&#8211;<xref rid="R29" ref-type="bibr">29</xref></sup> The
biological functions of miRs in T-ALL are largely unknown. To better understand
T-ALL pathogenesis and identify new therapeutic targets in T-ALL, we previously
developed a <italic>Pten</italic> knockout T-ALL mouse model.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> In this study, we profiled the miRs in the
Pten deficient mouse T-ALL. miR-26b was shown to be aberrantly expressed. Recent
studies have implicated aberrant expression of miR-26b in several types of
non-hematopoietic cancer.<sup><xref rid="R31" ref-type="bibr">31</xref>&#8211;<xref rid="R33" ref-type="bibr">33</xref></sup> However,
the expression level of miR-26b and its role in T-ALL is unknown. In this study, we
investigated the expression level of miR-26b in T-ALL, showed its aberrant
expression, and studied the effects of its altered expression on human T-ALL
cells.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S3"><title>Patient samples</title><p id="P6">We obtained 27 bone marrow samples from newly diagnosed T-ALL patients,
from 2009 to 2013, accessioned at the Institute of Hematology and Blood Disease
Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
Tianjin, PR China. The median patient age was 26 years old (range
18&#8211;66). The median percentage of blasts in bone marrow was 92%
(range, 80%&#8211;98%). The diagnosis of T-ALL in all cases
was established on the basis of morphologic findings, and immunophenotypic,
cytogenetic, and molecular data according to the World Health Organization (WHO)
classification and the National Comprehensive Cancer Network (NCCN) guidelines.
Mononuclear bone marrow cells were separated using Ficoll-Hypaque density
gradient centrifugation and stored in liquid nitrogen. This study was approved
by the Institutional Review Boards of the Institute of Hematology and Blood
Disease Hospital and informed consent was obtained from each patient according
to the revised Declaration of Helsinki.</p></sec><sec id="S4"><title>Cell lines and thymocytes</title><p id="P7">The human T-ALL cell lines CCRF-CEM, KOPT-K1, MOLT4, JURKAT, LOUCY, SUPT1
and the 293T cell line were purchased from American Type Culture Collection
(Manassas, VA, USA) and recently identified by DNA fingerprint. Two human
postnatal normal thymocyte samples were provided by Dr. Andrew Weng (Terry Fox
Laboratory, Canada). The mouse T-ALL cell lines (LPN248, LPN236, LPN228) were
generated from mouse <italic>Pten</italic> knock-out T-ALL models and LPN211 was
generated from <italic>Ink4a/Arf</italic> knock-out mice.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> The CCRF-CEM-FFluc cell line was
obtained from Dr. Malcolm K. Brenner and was described previously.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> The cell lines were cultured
in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and 10 mM L-glutamine. 293T cells were cultured in
Dulbecco&#8217;s Modified Eagle Media (DMEM) with 10% FBS. Cells were
kept at 37&#176;C in 5% CO2 and tested without cytoplasm
contamination.</p></sec><sec id="S5"><title>miRNA expression profiling</title><p id="P8">RNA labeling and hybridization on miRNA microarray chips were performed
as described.<sup><xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref></sup> Briefly, 5 &#956;g of total RNA from
each sample was biotin-labeled by reverse transcription using 5&#8242; biotin
end-labeled random octomer oligo primers. Hybridization of biotin-labeled cDNA
was carried out on a miRNA microarray chip (MD Anderson miRNA expression
Bioarray Version 5), which contains 2300 miRNA probes, including 1400 human and
900 mouse miRNA genes, in duplicate. Hybridization signals were detected by
biotin binding of a streptavidin&#8211;Alexa647 conjugate b using Axon Scanner
4000B (Axon Instruments, Union City, CA). The images were quantified by GENEPIX
6.0 software (Axon Instruments).</p></sec><sec id="S6"><title>Murine xenograft model</title><p id="P9">10 female 8 week-old Non-obese diabetic/severe combined immune deficient
gamma (NSG) mice (Jackson Laboratory, Sacramento, CA, USA) were randomly divided
into 2 groups and transplanted intravenously with CCRF-CEM-FFluc cells (5 mice
in control group: pCDH empty vector lentivirus infected; 5 mice in miR-26b
overexpressed group: pCDH-miR-26b lentivirus infected). The engraftment of
CCRF-CEM-FFluc was monitored by flow cytometry (anti-human CD45-APC antibody (BD
Biosciences, San Jose, CA, USA) and GFP on mouse retro-orbital bleeding samples.
Phospho-AKT was measured by intracellular staining flow cytometry (Cell
Signaling; #11962) on mixed mouse retro-orbital bleeding samples.
Transplanted mice underwent <italic>in vivo</italic> bioluminescence imaging at
various time points. The mice in each group were followed for survival. 2 groups
of the mice were treated and experimented under the same condition. This study
was approved by Institutional Review Board (IRB) the University of Texas MD
Anderson Cancer Center.</p></sec><sec id="S7"><title>Statistical analysis</title><p id="P10">Statistical analyses were performed and figures created using Graphpad
Prism software 6.0 (Graphpad software Inc, La Jolla, CA, USA). Each data point
represents the mean and standard deviation (SD) of experiments performed at
least in triplicate. The group data comparisons were performed using Student
<italic>t</italic> test, Two-way ANOVA and &#967;<sup>2</sup> test. Liner
regression was carried out to test the correlation between miR-26b and
<italic>PTEN</italic> expression level. The Kaplan Meier method was used to
generate survival curve. The P-values were two-sided and P&lt;0.05 was
considered significant.</p><p id="P11">Additional methods are presented in the <xref rid="SD1" ref-type="supplementary-material">supplementary data</xref>.</p></sec></sec><sec sec-type="results" id="S8"><title>Results</title><sec id="S9"><title>Expression of miR-26b is decreased in mouse T-ALL cells null for Pten and in
human T-ALL cell lines</title><p id="P12">We generated a mouse T-ALL model with deletion of the Pten tumor
suppressor gene and profiled the miRs from this model.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> A miR array identified a subset of miRs
that show aberrant expression levels in <italic>Pten</italic> deficient mouse
T-ALL cells (ArrayExpress database E-MTAB-5053) (<xref rid="F1" ref-type="fig">Figure 1A</xref>). We selected miR-26b for this study as its expression
level was significantly lower (&#8722;3.32 fold) in the <italic>Pten</italic>
deficient mouse T-ALL samples (n=4) as compared with mouse wild-type
(WT) thymocytes (n=2). In addition, aberrant expression of miR-26b has
been identified in several types of non-hematopoietic cancer.<sup><xref rid="R31" ref-type="bibr">31</xref>&#8211;<xref rid="R33" ref-type="bibr">33</xref></sup> To further validate that miR-26b is
down-regulated in the <italic>Pten</italic> deficient mouse T-ALL, a
quantitative RT-PCR (qRT-PCR) was performed. Indeed, the expression level of
miR-26b in the <italic>Pten</italic> deficient mouse T-ALL cells was markedly
lower in comparison to that of WT thymocytes and <italic>Ink4a/Arf</italic>
knock-out (KO) mouse T-ALL cells (LPN211) (<xref rid="F1" ref-type="fig">Figure
1B</xref>). The decreased expression level of miR-26b in
<italic>Pten</italic> deficient mouse T-ALL along with its potential role in
the pathogenesis of human T-ALL led us to explore if miR-26b expression levels
are also altered in human T-ALL. We first performed quantitative RT-PCR on a
panel of human T-ALL cell lines. Indeed, the expression level of miR-26b is
significantly lower (6 to 8 fold) in human T-ALL cell lines, including the PTEN
wild type cell lines SUP-T1 and KOPT-K1, and PTEN null cell lines CCRF-CEM,
LOUCY, JURKAT and MOLT4), when compared with that of normal human thymocytes
(<xref rid="F1" ref-type="fig">Figure 1C</xref>). miR-26b expression level
in human primary T-ALL were also determined by Quantitative RT-PCR. We selected
27 primary bone marrow T-ALL samples. miR-26b was found to be down-regulated in
the primary T-ALL cells compared with normal human thymocytes (P&lt;0.0001,
<xref rid="F1" ref-type="fig">Figure 1D</xref>), and miR-26b expression
levels correlated with PTEN expression level in primary human T-ALL samples
(<xref rid="F1" ref-type="fig">Figure 1E</xref>, r=0.3987,
P=0.039). These data indicate that miR-26b expression level is
consistently decreased in mouse and human T-ALL cells and is associated with
<italic>PTEN</italic> level.</p></sec><sec id="S10"><title>miR-26b inhibits proliferation and promotes apoptosis in T-ALL cells
<italic>in vitro</italic></title><p id="P13">To functionally assess whether miR-26b plays a role in the growth of
human T-ALL cells, we expressed exogenous miR-26b in a panel of human T-ALL cell
lines (<xref rid="F2" ref-type="fig">Figure 2A</xref>). In contrast with the
expression levels of miR-26b in empty vector infected T-ALL cells, T-ALL cells
infected with lentivirus expressing exogenous miR-26b showed modestly elevated
mRNA levels of miR-26b (P &lt; 0.05) in CCRF-CEM cells (2.2 fold higher), and
Koptk1 and Molt4 T-ALL cells (approximately 5 fold higher). Exogenous expression
of miR26b significantly reduced the proliferation of T-ALL cells (P &lt; 0.05)
with the most significant inhibition in Molt4 cells (<xref rid="F2" ref-type="fig">Figure 2B</xref>). In addition, the effects of exogenous
miR-26b on apoptosis of T-ALL cells were evaluated by flow cytometry using
Annexin-V and 7-AAD stains. Indeed, the expression of miR-26b significantly
increased the apoptosis of all of the three human T-ALL cell lines (<xref rid="F2" ref-type="fig">Figure 2C</xref>, P &lt; 0.05). CCRF-CEM, with
expression of miR-26b, showed 49.49% apoptosis (42.6% early
apoptosis in Q3 and 6.89% late apoptosis in Q2). In contrast, CCRF-CEM
with only vector showed 3.48% of apoptosis (2.5% early apoptosis
in Q3 and 0.98% late apoptosis in Q2). Similarly, expression of
exogenous miR-26 in KOPT-K1 and MOLT4 cells showed increased apoptosis,
51% apoptosis (15.9% early apoptosis in Q3 and 35.1%
late apoptosis in Q2) and 56.3% apoptosis (18.8% early apoptosis
in Q3 and 37.5% late apoptosis in Q2), respectively. Vector infected
KOPT-K1 and MOLT4 exhibited much lower apoptosis, 14.98% (1.88%
early apoptosis in Q3 and 13.1% late apoptosis in Q2) and 19.4%
(7.8% early apoptosis in Q3 and 11.6% late apoptosis in Q2),
respectively. These results suggest that miR-26b has tumor suppressor activities
and may be important in T-ALL pathogenesis.</p></sec><sec id="S11"><title>miR-26b inhibits the growth of T-ALL cells <italic>in vivo</italic></title><p id="P14">To evaluate the effect of miR-26b on the growth of T-ALL <italic>in
vivo</italic>, we established a T-ALL cell line xenograft model by injecting
vector-control and miR-26b overexpressed CCRF-CEM-FFluc cells into NSG mice.
Bioluminescence imaging showed that the growth of miR-26b overexpressing T-ALL
cells was significantly slower than that of control cells (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The mice with vector treated T-ALL cells
demised by 18 days and showed extensive T-ALL involving peripheral blood (<xref rid="F3" ref-type="fig">Figure 3B and C</xref>, P&lt;0.05,). In contrast,
mice with the expression of exogenous miR-26b had a prolonged overall survival
(<xref rid="F3" ref-type="fig">Figure 3C</xref>, P=0.0031). The
miR-26b overexpressing mice also exhibited lower phospho-AKT levels in the
CCRF-CEM-FFluc T-ALL cells, as detected by flow cytometry (<xref rid="F3" ref-type="fig">Figure 3B</xref>, P&lt;0.05). These data indicate that
miR-26b suppresses the growth of T-ALL cells <italic>in vivo.</italic></p></sec><sec id="S12"><title>miR-26b directly targets <italic>PIK3CD</italic> and inhibits PI3K/AKT
signaling</title><p id="P15">Because miRs exert their functions through targeting gene expression, we
performed bioinformatic analysis and screening to identify possible miR-26b
targets (<ext-link ext-link-type="uri" xlink:href="http://www.microrna.org">http://www.microrna.org</ext-link>). One of the potential target genes of
miR-26b is <italic>PIK3CD</italic> that encodes PI3K p110&#948;.
<italic>PIK3CD</italic> was selected as a miR-26b target gene because of the
well matched 3&#8242;-UTR binding site by miR-26b and its potential role in
hematologic malignancies.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> To
confirm if miR-26b binds to the 3&#8242;-UTR of <italic>PIK3CD</italic>, we
cloned the 3&#8242;-UTR of <italic>PIK3CD</italic> into a dual luciferase
vector. The dual-luciferase assay showed that miR-26b inhibited luciferase
activity with wt-<italic>PIK3CD</italic>-3&#8242;-UTR co-transfection compared
with vector (P&lt;0.001), but did not influence luciferase activity with
Mut-<italic>PIK3CD</italic>-3&#8242;-UTR or
Null-<italic>PIK3CD</italic>-3&#8242;-UTR co-transfection (P&gt;0.05) (<xref rid="F4" ref-type="fig">Figure 4A&#8211;B</xref>). The inhibitory effect
of miR-26b on <italic>PIK3CD</italic>-3&#8242;-UTR was also confirmed by
detecting PIK3CD protein (PI3K p110&#948;) level after overexpressing miR-26b
in T-ALL cell lines. Binding of miR-26b to the 3&#8242;-UTR of
<italic>PIK3CD</italic> mRNA inhibited protein translation of the PI3K
p110&#948; in CCRF-CEM, KOPTK1 and MOLT4 T-ALL cells (<xref rid="F4" ref-type="fig">Figure 4C</xref>). To assess the effect of the decreased PI3K
p110&#948; on PI3K/AKT pathway, Western blot analysis was used to determine
p-AKT expression levels. Phosphorylated-AKT was reduced in T-ALL cells with
miR-26b overexpression compared with vector control (<xref rid="F4" ref-type="fig">Figure 4C</xref>). Additionally, co-expression of exogenous
miR-26b and PIK3CD can significantly rescue the miR-26b effect on apoptosis in
CCRF-CEM cells (<xref rid="SD2" ref-type="supplementary-material">Supplemental
Figure 1</xref>). These results suggest that <italic>PIK3CD</italic> is a
direct target of miR-26b.</p></sec><sec id="S13"><title>Inhibition of PIK3CD by CAL-101 or shRNAs reduces the growth of T-ALL
cells</title><p id="P16">Because the PI3K pathway is frequently altered in T-ALL, we hypothesized
that decreased expression of PI3K p110&#948; affects the growth and survival
of T-ALL cells. T-ALL cells, including CCRF-CEM, KOPT-K1 and MOLT4, were treated
with various concentrations of CAL-101 (Idelalisib, GS-1101), a selective
p110&#948; inhibitor.<sup><xref rid="R38" ref-type="bibr">38</xref></sup>
CAL-101 demonstrated a dose-dependent inhibition of T-ALL viability, indicating
that inhibition of p110&#948; reduces the growth in T-ALL cells (<xref rid="F5" ref-type="fig">Figure 5A</xref>). Next we confirmed these findings
by reducing the expression level of PIK3CD with two <italic>PIK3CD</italic>
shRNAs. The shRNAs significantly dampened the expression level of the PI3K
p110&#948; in CCRF-CEM and KOPT-K1 T-ALL cells as shown by Western blotting
(<xref rid="F5" ref-type="fig">Figure 5B</xref>). Compared with vector
treated cells, T-ALL cells infected with the two shRNAs showed markedly
decreased proliferation and increased apoptosis (<xref rid="F5" ref-type="fig">Figure 5C</xref>). Thus, PIK3CD is important for the growth and survival of
T-ALL cells, suggesting that miR-26b-mediated downregulation of PIK3CD may have
a direct impact on T-ALL pathogenesis.</p></sec><sec id="S14"><title>miR-26b is regulated by the PTEN/PI3K pathway via the transcriptional factor
IKZF1</title><p id="P17">miR-26b is frequently down-regulated in T-ALL, and this downregulation
is important for the growth and survival of T-ALL cells. Therefore, we were
interested in determining how miR-26b is regulated. Since miR-26b is
downregulated in <italic>Pten</italic> deficient mouse T-ALL cell lines and
human T-ALL cell lines, we hypothesized that the PTEN/PI3K pathway affects the
expression level of miR-26b. Interestingly, restoration of PTEN expression in
PTEN<sup>null</sup> human T-ALL cell lines (CCRF-CEM and MOLT4) that lack
endogenous PTEN expression significantly elevated the expression level of
miR-26b (<xref rid="F6" ref-type="fig">Figure 6A</xref>, P&lt;0.05). Expression
of exogenous PTEN in the KOPT-K1 that has endogenous PTEN expression had no or
minimal impact on miR-26b expression (<xref rid="F6" ref-type="fig">Figure
6A</xref>, P&gt;0.05). In contrast, knocking-down PTEN in KOPT-K1 cells by
shRNAs down-regulated miR-26b levels (<xref rid="F6" ref-type="fig">Figure
6B</xref>, P&lt;0.05). Those data indicate that PTEN/PI3K pathway regulates
miR-26b.</p><p id="P18">Recent studies have shown that lack of PTEN, which negatively regulates
PI3K signaling, alters the expression of different isoforms of the tumor
suppressor Ikaros,<sup><xref rid="R39" ref-type="bibr">39</xref></sup> leading
us to hypothesize that the PTEN/PI3K pathway may modulate miR-26b through
modulation of Ikaros activity. Ikaros protein has several isoforms that are
divided into two groups: dominant positive ones (IK-DP, including IK1-IK3) and
dominant negative ones (IK-DN, including IK4-9). In this study, we identified
two predominant Ikaros isoforms in the CCRF-CEM, MOLT4 and KOPT-K1 cell lines
(<xref rid="F6" ref-type="fig">Figure 6C</xref>). We cloned and sequenced
the two isoforms. One was IK1 that is the longest IK-DP isoform (<xref rid="F6" ref-type="fig">Figure 6C</xref>). The other one is a novel Ikaros isoform
that retained the DBD, lost most of the C-terminal zinc finger domain for
polymerization, and showed barely detectable expression levels in normal
thymocytes (<xref rid="F6" ref-type="fig">Figure 6C</xref> and <xref rid="SD3" ref-type="supplementary-material">Supplemental Figure 2A&#8211;B</xref>).
Additionally, the novel isoform also had an in-frame deletion of 30 nucleotides
that encode 10 amino acids right before the C-terminal zinc finger domain (<xref rid="SD3" ref-type="supplementary-material">Supplemental Figure
2A&#8211;B</xref>). The other Ikaros DP or DN isoforms were not detectable
by Western blotting (data not shown).</p><p id="P19">To assess whether Ikaros, the IKZF1 gene coding protein, binds to the
promoter of miR-26b, we performed a search for a binding site(s). Bioinformatic
analysis by PROMO 3.0 (<ext-link ext-link-type="uri" xlink:href="http://alggen.lsi.upc.es/recerca/menu_recerca.html">http://alggen.lsi.upc.es/recerca/menu_recerca.html</ext-link>) predicted
that Ikaros binds to the miR-26b promoter region as a transcriptional factor.
There are five potential IK1 binding sites that have a core GGGAA sequence,
according to the Ikaros ChIP-seq report.<sup><xref rid="R40" ref-type="bibr">40</xref></sup> To confirm that IK1 specifically binds to the site(s)
in the miR-26b promoter region, we overexpressed a Flag-tagged version of the
Ikaros isoform IK1 in CCRF-CEM, MOLT4, and KOPT-K1 cells (<xref rid="F6" ref-type="fig">Figure 6D</xref>). The expression of exogenous IK1
significantly elevated miR-26b expression levels. In addition, a ChIP assay was
performed in the CCRF-CEM cell line, and the ChIP PCR primers recovered two
GGGAA cores on the promoter region. Ikaros-antibody, which can bind to all
Ikaros isoforms, was used to precipitate crosslinked DNA from CCRF-CEM cells
that were infected by empty lentivirus vector or PTEN overexpression lentivirus.
Flag antibody was used to precipitate crosslinked DNA from CCRF-CEM cells that
were infected with lentivirus overexpressing Flag-tagged IK1 (IK1-Flag). We
found that more Ikaros protein was bound to the miR-26b promoter region in
CCRF-CEM cells when PTEN or IK1 was overexpressed in CCRF-CEM cells. In
contrast, there was very weak or no binding of Ikaros protein in empty vector
lentivirus infected CCRF-CEM (control) cells (<xref rid="F6" ref-type="fig">Figure 6E</xref>).</p><p id="P20">To further confirm that the transcriptional factor IK1 binds to the
miR-26b promoter as a transcription factor, we generated a pGL3 luciferase
reporter vector with an inserted miR-26b promoter region. This construct was
co-transfected with IK1 expression plasmid (designated as Ikaros-DP) or vector
control into 293T cells. We found that luciferase activity was significantly
higher in 293T cells with the miR-26b promoter region than in those with the
empty vector (p&lt;0.01, <xref rid="F6" ref-type="fig">Figure 6F</xref>). As the
novel isoform of Ikaros (IK-DN) had an in-frame deletion and loss of most of the
C-terminal zinc finger, we hypothesized that it is a dominant negative isoform.
We generated a construct that expresses Ikaros-DN. Interestingly,
co-transfection of IK-DN with IK1 expression plasmid significantly diminished
the IK1 dependent luciferase activity in 293-T cells (p&lt;0.05, <xref rid="F6" ref-type="fig">Figure 6F</xref>). Since PTEN expression elevates miR-26b
expression, we hypothesized that PTEN expression differentially modulates the
expression of IK-DP and IK-DN in T-ALL cells. To this end, the three T-ALL cell
lines (CCRF-CEM, MOLT4 and KOPT-K1) were infected with PTEN expression
lentivirus. Expression of PTEN markedly decreased the levels of IK-DN isoform in
CCRF-CEM and MOLT4, two T-ALL cell lines that have no endogenous PTEN expression
(<xref rid="F6" ref-type="fig">Figure 6G</xref>). Exogenous expression of
PTEN had no significant impact on the IK-DN isoform expression in KOPT-K1, a
T-ALL cell line with endogenous PTEN expression. However, knocking-down PTEN by
shRNAs increased the level of IK-DN isoform in the KOPT-K1 cell line (<xref rid="F6" ref-type="fig">Figure 6H</xref>). Interestingly, expression of
exogenous PTEN or knocked-down PTEN has no significant effect on the expression
level of IK-DP isoform in any of the T-ALL cell lines, regardless of the
presence of endogenous PTEN expression (<xref rid="F6" ref-type="fig">Figure 6G
and H</xref>). Taken together, these data suggest that miR-26b is regulated
by the Pten/PI3K pathways through altered splicing isoforms of Ikaros.</p></sec></sec><sec sec-type="discussion" id="S15"><title>Discussion</title><p id="P21">Activation of the PI3K/AKT pathway occurs frequently in T-ALL and has
emerged as a potential therapeutic target.<sup><xref rid="R41" ref-type="bibr">41</xref>, <xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup> Our study showed that miR-26b directly
targets <italic>PIK3CD</italic>, the gene encoding the PI3K p110&#948; isoform,
and inhibits T-ALL cell proliferation by inactivating the PI3K/AKT pathway
<italic>in vitro</italic> and <italic>in vivo</italic>. Furthermore, we showed
that CAL-101, a selective PI3K p110 &#948; inhibitor, reduces proliferation and
promotes apoptosis in T-ALL cell lines. The T-ALL cell lines we studied have
constitutively activated PI3K activity. Two of the T-ALL cell lines (CCRF-CEM and
MOLT4) do not express PTEN and the third T-ALL cell line (KOPT-K1) expresses PTEN,
suggesting that the presence of PI3K p110&#948; is not totally dependent on PTEN
and may be activated by other mechanism(s).</p><p id="P22">Since PTEN is not a transcription factor, but likely affects the expression
of miR-26 via transcription factor(s), we screened for transcriptional factors that
regulate miR-26b expression. Sequencing analysis revealed several potential Ikaros
core binding sites in the promoter region of miR-26b. Using a polyclonal antibody,
we found IK1 and a novel Ikaros isoform (IK-DN). The IK-DN retains the four
N-terminal zinc-finger DNA binding domain, but lacks 10 amino acids encoded by exon
7 and most of the 3&#8242;-end C-terminal zinc-finger polymerization domain.
Previously, others have shown that PTEN loss activates the PI3K/AKT pathway and
aberrant Ikaros dominant negative isoforms are expressed in p53 mouse T-ALL
cells.<sup><xref rid="R44" ref-type="bibr">44</xref></sup> PI3K/AKT
signaling mediates inappropriate Ikaros mRNA splicing by downregulation of FoxO1 in
PTEN<sup>&#8722;/&#8722;</sup> pro-B cells.<sup><xref rid="R39" ref-type="bibr">39</xref></sup> Exogenous PTEN expression led to increased
expression of FoxO1 in T-ALL cell lines with null endogenous PTEN (CCRF-CEM and
MOLT4). Thus, this could be one of the mechanisms of Ikaros regulation. In contrast,
FoxO1 expression level was not changed in the PTEN wt T-ALL cell line KOPT-K1 upon
the expression of exogenous PTEN. Future research on this mechanism might be
fruitful (data not shown). As a transcriptional factor, Ikaros binds DNA as dimeric
and multimeric complexes and specific Ikaros isoforms influence their
functions.<sup><xref rid="R45" ref-type="bibr">45</xref>, <xref rid="R46" ref-type="bibr">46</xref></sup> Dominant negative Ikaros isoforms modulate
Ikaros transcriptional complexes during transcription initiation, elongation or
termination.<sup><xref rid="R47" ref-type="bibr">47</xref>&#8211;<xref rid="R49" ref-type="bibr">49</xref></sup> Co-expression of dominant positive
and dominant negative Ikaros in a transcriptional complex could alter its affinity
for pericentromeric heterochromatin, leading to chromatin remodeling and activation
of target genes.<sup><xref rid="R50" ref-type="bibr">50</xref></sup></p><p id="P23">The ChIP assay confirmed the presence of two Ikaros core binding sites that
are adjacent to each other (<xref rid="F6" ref-type="fig">Figure 6D</xref> and <xref rid="SD4" ref-type="supplementary-material">Supplement Figure 3</xref>).
Overexpression of IK1, the strongest functional isoform of Ikaros, significantly
induced miR-26b expression in CCRF-CEM, MOLT4, and KOPT-K1 cell lines. The IK-DN
retains the 4 N-terminal zinc-finger DNA binding domain, which explains its
remaining binding activity to the miR-26b promoter (<xref rid="F6" ref-type="fig">Figure 6E</xref>). However, this binding is much weaker than that of IK1 (<xref rid="F6" ref-type="fig">Figure 6E</xref>). Moreover, the novel Ikaros isoform
functions similarly to the dominant negative isoforms of Ikaros as its presence
strongly diminished the binding activities of IK1 to the miR-26 promoter. This
observation suggests there is potentially competitive binding of the novel IK-DN and
IK1 to the miR-26b promoter. The finding of a differential impact of PTEN on the
expression of IK1 and the novel isoform is intriguing (<xref rid="F6" ref-type="fig">Figure 6G</xref>). The finding that the novel isoform of IK-DN, but not IK1, is
regulated after exogenous PTEN expression or knocking-down along with the fact that
IK1 expression enhances the binding of Ikaros to the miR-26b promoter region
indicate that Ikaros may regulate miR-26b in both a dose- and isoform-dependent
manner in human T-ALL cells. Previous studies have shown that Ikaros isoforms
competitively form dimer or polymer complexes to affect gene transcription. Reduced
expression of the novel Ikaros isoform may relatively increase dominant-positive
IK1, or vice versa, therefore regulating miR-26b expression (<xref rid="F6" ref-type="fig">Figure 6F</xref> and <xref rid="F7" ref-type="fig">Figure
7</xref>).</p><p id="P24"><italic>NOTCH1</italic> is frequently mutated and thought to be oncogenic in
T-ALL.<sup><xref rid="R51" ref-type="bibr">51</xref></sup> We hypothesized
that miR-26b may have an effect on NOTCH1. Interestingly, expression of exogenous
miR-26b with lentivirus diminished the levels of NOTCH1 and its downstream target
HES-1 in the T-ALL cell lines--CCRF-CEM, KOPT-K1, and MOLT4 (<xref rid="SD5" ref-type="supplementary-material">Supplementary Figure 4</xref>). However, there
is no consensus miR-26b binding site in the 3&#8242;UTR of <italic>NOTCH1</italic>
(data not shown), suggesting that miR-26b may downregulate the Notch pathway
indirectly. T-ALL cells often display chronic activation of PI3K/AKT associated with
Notch activation.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> Inhibition of
both the PI3K and Notch1 pathways may be beneficial for T-ALL treatment and further
characterization of miR-26b and its regulation of target genes may lead to targeted
T-ALL therapy.</p><p id="P25">In summary, miR-26b is involved in the pathogenesis of T-ALL by targeting
<italic>PIK3CD</italic> of the PI3K/AKT pathway and indirectly regulating the
Notch pathway. The tumor suppressor PTEN inhibits the PI3K pathway which alters
isoforms of Ikaros, and is one of the up-regulators of miR-26b in T-ALL (<xref rid="F7" ref-type="fig">Figure 7</xref>). In this circle of PI3K modulation, a
therapeutic PI3K inhibitor may be helpful in treating patients with T-ALL. Further
studies of the target genes and regulators of miR-26b may pave the road to the
development of improved therapy for T-ALL patients.</p></sec><sec sec-type="supplementary-material" id="S16"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>1</label><media xlink:href="NIHMS855382-supplement-1.docx" orientation="portrait" xlink:type="simple" id="d36e889" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>2</label><media xlink:href="NIHMS855382-supplement-2.tif" orientation="portrait" xlink:type="simple" id="d36e893" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>3</label><media xlink:href="NIHMS855382-supplement-3.tif" orientation="portrait" xlink:type="simple" id="d36e897" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>4</label><media xlink:href="NIHMS855382-supplement-4.tif" orientation="portrait" xlink:type="simple" id="d36e901" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><label>5</label><media xlink:href="NIHMS855382-supplement-5.tif" orientation="portrait" xlink:type="simple" id="d36e905" position="anchor"/></supplementary-material></sec></body><back><ack id="S17"><p>This work was partially supported by NIH/NCI R01 CA164346 and R01 CA200703, CPRIT
RP140402, Developmental Research Awards in Leukemia SPORE CA100632, Ladies Leukemia
League, and American Cancer Society IRG, Center for Genetic and Genomics, Center for
Inflammation and Cancer, Physician Scientist Award and IRG of UT MD Anderson Cancer
Center to M.J.Y. This work was also supported by the Sister Institution Network
Funds of UT MD Anderson Cancer Center to M.J.Y, and matching fund from Tianjin
Medical University Cancer Institute and Hospital to Y.Z. and matching fund from
Shanghai Cancer Center to X.Y.Z. The postnatal normal thymocytes were generously
provided by Dr. Andrew P. Weng at Terry Fox Laboratory, Canada. The CCRF-CEM-FFluc
cell line was kindly provided by Dr. Malcolm K. Brenner at Texas Children&#8217;s
Hospital and Houston Methodist Hospital, Houston, TX, USA. miRNA expression
profiling was performed at the core for Sequencing and ncRNA Program at the
University of Texas MD Anderson Cancer Center. RNAseq was performed at the
Sequencing and Microarray Facility at the University of Texas MD Anderson Cancer
Center. Dr. Patrick A, Zweidler-McKay is currently working at ImmunoGen Inc. (830
Winter Street, Waltham, MA, USA).</p></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p><bold>Conflicts of Interest:</bold> No potential conflicts of interest were
disclosed.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrando</surname><given-names>AA</given-names></name><name><surname>Neuberg</surname><given-names>DS</given-names></name><name><surname>Staunton</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Huard</surname><given-names>C</given-names></name><name><surname>Raimondi</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Gene expression signatures define novel oncogenic pathways in T
cell acute lymphoblastic leukemia</article-title><source>Cancer Cell</source><year>2002</year><month>2</month><volume>1</volume><issue>1</issue><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">12086890</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>DI</given-names></name><name><surname>Paietta</surname><given-names>EM</given-names></name><name><surname>Moorman</surname><given-names>AV</given-names></name><name><surname>Richards</surname><given-names>SM</given-names></name><name><surname>Buck</surname><given-names>G</given-names></name><name><surname>DeWald</surname><given-names>G</given-names></name><etal/></person-group><article-title>T-cell acute lymphoblastic leukemia in adults: clinical features,
immunophenotype, cytogenetics, and outcome from the large randomized
prospective trial (UKALL XII/ECOG 2993)</article-title><source>Blood</source><year>2009</year><month>12</month><day>10</day><volume>114</volume><issue>25</issue><fpage>5136</fpage><lpage>5145</lpage><pub-id pub-id-type="pmid">19828704</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Robison</surname><given-names>LL</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name></person-group><article-title>Acute lymphoblastic leukaemia</article-title><source>Lancet</source><year>2008</year><month>3</month><day>22</day><volume>371</volume><issue>9617</issue><fpage>1030</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">18358930</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name></person-group><article-title>Treatment of acute lymphoblastic leukemia</article-title><source>N Engl J Med</source><year>2006</year><month>1</month><day>12</day><volume>354</volume><issue>2</issue><fpage>166</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">16407512</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Yunes</surname><given-names>JA</given-names></name><name><surname>Cardoso</surname><given-names>BA</given-names></name><name><surname>Martins</surname><given-names>LR</given-names></name><name><surname>Jotta</surname><given-names>PY</given-names></name><name><surname>Abecasis</surname><given-names>M</given-names></name><etal/></person-group><article-title>PTEN posttranslational inactivation and hyperactivation of the
PI3K/Akt pathway sustain primary T cell leukemia viability</article-title><source>J Clin Invest</source><year>2008</year><month>11</month><volume>118</volume><issue>11</issue><fpage>3762</fpage><lpage>3774</lpage><pub-id pub-id-type="pmid">18830414</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>S</given-names></name><name><surname>Kirkwood</surname><given-names>AA</given-names></name><name><surname>Goulden</surname><given-names>N</given-names></name><name><surname>Vora</surname><given-names>A</given-names></name><name><surname>Linch</surname><given-names>DC</given-names></name><name><surname>Gale</surname><given-names>RE</given-names></name></person-group><article-title>Impact of PTEN abnormalities on outcome in pediatric patients
with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003
trial</article-title><source>Leukemia</source><year>2016</year><month>1</month><volume>30</volume><issue>1</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">26220040</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastner</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name></person-group><article-title>Role of Ikaros in T-cell acute lymphoblastic
leukemia</article-title><source>World journal of biological chemistry</source><year>2011</year><month>6</month><day>26</day><volume>2</volume><issue>6</issue><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">21765975</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orozco</surname><given-names>CA</given-names></name><name><surname>Acevedo</surname><given-names>A</given-names></name><name><surname>Cortina</surname><given-names>L</given-names></name><name><surname>Cuellar</surname><given-names>GE</given-names></name><name><surname>Duarte</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><etal/></person-group><article-title>The combined expression patterns of Ikaros isoforms characterize
different hematological tumor subtypes</article-title><source>PloS one</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e82411</fpage><pub-id pub-id-type="pmid">24324784</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geimer Le Lay</surname><given-names>AS</given-names></name><name><surname>Oravecz</surname><given-names>A</given-names></name><name><surname>Mastio</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Marchal</surname><given-names>P</given-names></name><name><surname>Ebel</surname><given-names>C</given-names></name><etal/></person-group><article-title>The tumor suppressor Ikaros shapes the repertoire of notch target
genes in T cells</article-title><source>Sci Signal</source><year>2014</year><month>3</month><day>18</day><volume>7</volume><issue>317</issue><fpage>ra28</fpage><pub-id pub-id-type="pmid">24643801</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winandy</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Georgopoulos</surname><given-names>K</given-names></name></person-group><article-title>A dominant mutation in the Ikaros gene leads to rapid development
of leukemia and lymphoma</article-title><source>Cell</source><year>1995</year><month>10</month><day>20</day><volume>83</volume><issue>2</issue><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">7585946</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>MH</given-names></name><name><surname>Ji</surname><given-names>XQ</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>XJ</given-names></name></person-group><article-title>miR-590 promotes cell proliferation and invasion in T-cell acute
lymphoblastic leukaemia by inhibiting RB1</article-title><source>Oncotarget</source><year>2016</year><month>3</month><day>28</day></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>SJ</given-names></name><name><surname>Li</surname><given-names>HB</given-names></name><name><surname>Cui</surname><given-names>G</given-names></name><name><surname>Kong</surname><given-names>XL</given-names></name><name><surname>Sun</surname><given-names>LL</given-names></name><name><surname>Zhao</surname><given-names>YQ</given-names></name><etal/></person-group><article-title>miRNA-149* promotes cell proliferation and suppresses
apoptosis by mediating JunB in T-cell acute lymphoblastic
leukemia</article-title><source>Leukemia research</source><year>2016</year><month>2</month><volume>41</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">26725775</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>JJ</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Zhan</surname><given-names>XR</given-names></name></person-group><article-title>MicroRNA-204 inhibits cell proliferation in T-cell acute
lymphoblastic leukemia by down-regulating SOX4</article-title><source>International journal of clinical and experimental pathology</source><year>2015</year><volume>8</volume><issue>8</issue><fpage>9189</fpage><lpage>9195</lpage><pub-id pub-id-type="pmid">26464665</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>LH</given-names></name><name><surname>Schiavinato</surname><given-names>JL</given-names></name><name><surname>Fraguas</surname><given-names>MS</given-names></name><name><surname>Lucena-Araujo</surname><given-names>AR</given-names></name><name><surname>Haddad</surname><given-names>R</given-names></name><name><surname>Araujo</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Potential roles of microRNA-29a in the molecular pathophysiology
of T-cell acute lymphoblastic leukemia</article-title><source>Cancer science</source><year>2015</year><month>10</month><volume>106</volume><issue>10</issue><fpage>1264</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">26251039</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Bai</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Bai</surname><given-names>W</given-names></name><etal/></person-group><article-title>Upregulation of miRNA-17 and miRNA-19 is associated with
unfavorable prognosis in patients with T-cell lymphoblastic
lymphoma</article-title><source>Experimental and molecular pathology</source><year>2015</year><month>10</month><volume>99</volume><issue>2</issue><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">26231295</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verduci</surname><given-names>L</given-names></name><name><surname>Azzalin</surname><given-names>G</given-names></name><name><surname>Gioiosa</surname><given-names>S</given-names></name><name><surname>Carissimi</surname><given-names>C</given-names></name><name><surname>Laudadio</surname><given-names>I</given-names></name><name><surname>Fulci</surname><given-names>V</given-names></name><etal/></person-group><article-title>microRNA-181a enhances cell proliferation in acute lymphoblastic
leukemia by targeting EGR1</article-title><source>Leukemia research</source><year>2015</year><month>4</month><volume>39</volume><issue>4</issue><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">25740602</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Miao</surname><given-names>MH</given-names></name><name><surname>Ji</surname><given-names>XQ</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>XJ</given-names></name></person-group><article-title>miR-664 negatively regulates PLP2 and promotes cell proliferation
and invasion in T-cell acute lymphoblastic leukaemia</article-title><source>Biochemical and biophysical research communications</source><year>2015</year><month>4</month><day>3</day><volume>459</volume><issue>2</issue><fpage>340</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">25735976</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanghvi</surname><given-names>VR</given-names></name><name><surname>Mavrakis</surname><given-names>KJ</given-names></name><name><surname>Van der Meulen</surname><given-names>J</given-names></name><name><surname>Boice</surname><given-names>M</given-names></name><name><surname>Wolfe</surname><given-names>AL</given-names></name><name><surname>Carty</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterization of a set of tumor suppressor microRNAs in T cell
acute lymphoblastic leukemia</article-title><source>Science signaling</source><year>2014</year><month>11</month><day>18</day><volume>7</volume><issue>352</issue><fpage>ra111</fpage><pub-id pub-id-type="pmid">25406379</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>M</given-names></name><name><surname>Bhatnagar</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>AP</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Sill</surname><given-names>H</given-names></name><etal/></person-group><article-title>A microRNA-mediated regulatory loop modulates NOTCH and MYC
oncogenic signals in B- and T-cell malignancies</article-title><source>Leukemia</source><year>2015</year><month>4</month><volume>29</volume><issue>4</issue><fpage>968</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">25311243</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mets</surname><given-names>E</given-names></name><name><surname>Van der Meulen</surname><given-names>J</given-names></name><name><surname>Van Peer</surname><given-names>G</given-names></name><name><surname>Boice</surname><given-names>M</given-names></name><name><surname>Mestdagh</surname><given-names>P</given-names></name><name><surname>Van de Walle</surname><given-names>I</given-names></name><etal/></person-group><article-title>MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB
oncogene in T-cell acute lymphoblastic leukemia</article-title><source>Leukemia</source><year>2015</year><month>4</month><volume>29</volume><issue>4</issue><fpage>798</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">25231743</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>D</given-names></name><name><surname>Kaul</surname><given-names>D</given-names></name><name><surname>Chauhan</surname><given-names>N</given-names></name><name><surname>Marwaha</surname><given-names>RK</given-names></name></person-group><article-title>miR-2909-mediated regulation of KLF4: a novel molecular mechanism
for differentiating between B-cell and T-cell pediatric acute lymphoblastic
leukemias</article-title><source>Molecular cancer</source><year>2014</year><volume>13</volume><fpage>175</fpage><pub-id pub-id-type="pmid">25037230</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mets</surname><given-names>E</given-names></name><name><surname>Van Peer</surname><given-names>G</given-names></name><name><surname>Van der Meulen</surname><given-names>J</given-names></name><name><surname>Boice</surname><given-names>M</given-names></name><name><surname>Taghon</surname><given-names>T</given-names></name><name><surname>Goossens</surname><given-names>S</given-names></name><etal/></person-group><article-title>MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute
lymphoblastic leukemia</article-title><source>Haematologica</source><year>2014</year><month>8</month><volume>99</volume><issue>8</issue><fpage>1326</fpage><lpage>1333</lpage><pub-id pub-id-type="pmid">24895337</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Aoyama</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Masaki</surname><given-names>A</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prognostic impact of microRNA-145 down-regulation in adult T-cell
leukemia/lymphoma</article-title><source>Human pathology</source><year>2014</year><month>6</month><volume>45</volume><issue>6</issue><fpage>1192</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">24745613</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimenes-Teixeira</surname><given-names>HL</given-names></name><name><surname>Lucena-Araujo</surname><given-names>AR</given-names></name><name><surname>Dos Santos</surname><given-names>GA</given-names></name><name><surname>Zanette</surname><given-names>DL</given-names></name><name><surname>Scheucher</surname><given-names>PS</given-names></name><name><surname>Oliveira</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Increased expression of miR-221 is associated with shorter
overall survival in T-cell acute lymphoid leukemia</article-title><source>Experimental hematology &amp; oncology</source><year>2013</year><volume>2</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="pmid">23566596</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Kuang</surname><given-names>S</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><etal/></person-group><article-title>MicroRNA and transcription factor co-regulatory network analysis
reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic
leukemia</article-title><source>Nucleic acids research</source><year>2012</year><month>7</month><volume>40</volume><issue>12</issue><fpage>5201</fpage><lpage>5214</lpage><pub-id pub-id-type="pmid">22362744</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavrakis</surname><given-names>KJ</given-names></name><name><surname>Van Der Meulen</surname><given-names>J</given-names></name><name><surname>Wolfe</surname><given-names>AL</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Mets</surname><given-names>E</given-names></name><name><surname>Taghon</surname><given-names>T</given-names></name><etal/></person-group><article-title>A cooperative microRNA-tumor suppressor gene network in acute
T-cell lymphoblastic leukemia (T-ALL)</article-title><source>Nature genetics</source><year>2011</year><month>7</month><volume>43</volume><issue>7</issue><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">21642990</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaretti</surname><given-names>S</given-names></name><name><surname>Messina</surname><given-names>M</given-names></name><name><surname>Tavolaro</surname><given-names>S</given-names></name><name><surname>Zardo</surname><given-names>G</given-names></name><name><surname>Elia</surname><given-names>L</given-names></name><name><surname>Vitale</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gene expression profiling identifies a subset of adult T-cell
acute lymphoblastic leukemia with myeloid-like gene features and
over-expression of miR-223</article-title><source>Haematologica</source><year>2010</year><month>7</month><volume>95</volume><issue>7</issue><fpage>1114</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">20418243</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schotte</surname><given-names>D</given-names></name><name><surname>Chau</surname><given-names>JC</given-names></name><name><surname>Sylvester</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>van der Velden</surname><given-names>VH</given-names></name><etal/></person-group><article-title>Identification of new microRNA genes and aberrant microRNA
profiles in childhood acute lymphoblastic leukemia</article-title><source>Leukemia</source><year>2009</year><month>2</month><volume>23</volume><issue>2</issue><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">18923441</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spizzo</surname><given-names>R</given-names></name><name><surname>Nicoloso</surname><given-names>MS</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>SnapShot: MicroRNAs in Cancer</article-title><source>Cell</source><year>2009</year><month>5</month><day>1</day><volume>137</volume><issue>3</issue><fpage>586</fpage><lpage>586</lpage><fpage>e581</fpage><pub-id pub-id-type="pmid">19410551</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medyouf</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Armstrong</surname><given-names>F</given-names></name><name><surname>Gusscott</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Gedman</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Acute T-cell leukemias remain dependent on Notch signaling
despite PTEN and INK4A/ARF loss</article-title><source>Blood</source><year>2010</year><month>2</month><day>11</day><volume>115</volume><issue>6</issue><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">20008304</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Moreno</surname><given-names>M</given-names></name><name><surname>Sharp</surname><given-names>T</given-names></name><name><surname>Goodheart</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>MicroRNA-26b represses colon cancer cell proliferation by
inhibiting lymphoid enhancer factor 1 expression</article-title><source>Molecular cancer therapeutics</source><year>2014</year><month>7</month><volume>13</volume><issue>7</issue><fpage>1942</fpage><lpage>1951</lpage><pub-id pub-id-type="pmid">24785257</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name></person-group><article-title>MicroRNA-26b suppresses the metastasis of non-small cell lung
cancer by targeting MIEN1 via NF-kappaB/MMP-9/VEGF pathways</article-title><source>Biochem Biophys Res Commun</source><year>2016</year><month>1</month><day>28</day></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>WD</given-names></name><name><surname>Zhou</surname><given-names>FL</given-names></name><name><surname>Lin</surname><given-names>N</given-names></name></person-group><article-title>MicroRNA-26b inhibits osteosarcoma cell migration and invasion by
down-regulating PFKFB3 expression</article-title><source>Genet Mol Res</source><year>2015</year><volume>14</volume><issue>4</issue><fpage>16872</fpage><lpage>16879</lpage><pub-id pub-id-type="pmid">26681033</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamonkin</surname><given-names>M</given-names></name><name><surname>Rouce</surname><given-names>RH</given-names></name><name><surname>Tashiro</surname><given-names>H</given-names></name><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><article-title>A T-cell-directed chimeric antigen receptor for the selective
treatment of T-cell malignancies</article-title><source>Blood</source><year>2015</year><month>8</month><day>20</day><volume>126</volume><issue>8</issue><fpage>983</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">26056165</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Meloon</surname><given-names>B</given-names></name><name><surname>Gamliel</surname><given-names>N</given-names></name><name><surname>Sevignani</surname><given-names>C</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><etal/></person-group><article-title>An oligonucleotide microchip for genome-wide microRNA profiling
in human and mouse tissues</article-title><source>Proceedings of the National Academy of Sciences of the United States of
America</source><year>2004</year><month>6</month><day>29</day><volume>101</volume><issue>26</issue><fpage>9740</fpage><lpage>9744</lpage><pub-id pub-id-type="pmid">15210942</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>MicroRNA expression profiling using microarrays</article-title><source>Nature protocols</source><year>2008</year><volume>3</volume><issue>4</issue><fpage>563</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">18388938</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Hoellenriegel</surname><given-names>J</given-names></name></person-group><article-title>Phosphoinositide 3&#8242;-kinase delta: turning off BCR
signaling in Chronic Lymphocytic Leukemia</article-title><source>Oncotarget</source><year>2011</year><month>10</month><volume>2</volume><issue>10</issue><fpage>737</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">22006556</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>KS</given-names></name><name><surname>Cheson</surname><given-names>B</given-names></name></person-group><article-title>The role of idelalisib in the treatment of relapsed and
refractory chronic lymphocytic leukemia</article-title><source>Therapeutic advances in hematology</source><year>2016</year><month>4</month><volume>7</volume><issue>2</issue><fpage>69</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">27054023</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhatib</surname><given-names>A</given-names></name><name><surname>Werner</surname><given-names>M</given-names></name><name><surname>Hug</surname><given-names>E</given-names></name><name><surname>Herzog</surname><given-names>S</given-names></name><name><surname>Eschbach</surname><given-names>C</given-names></name><name><surname>Faraidun</surname><given-names>H</given-names></name><etal/></person-group><article-title>FoxO1 induces Ikaros splicing to promote immunoglobulin gene
recombination</article-title><source>The Journal of experimental medicine</source><year>2012</year><month>2</month><day>13</day><volume>209</volume><issue>2</issue><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">22291095</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schjerven</surname><given-names>H</given-names></name><name><surname>McLaughlin</surname><given-names>J</given-names></name><name><surname>Arenzana</surname><given-names>TL</given-names></name><name><surname>Frietze</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Wadsworth</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Selective regulation of lymphopoiesis and leukemogenesis by
individual zinc fingers of Ikaros</article-title><source>Nature immunology</source><year>2013</year><month>10</month><volume>14</volume><issue>10</issue><fpage>1073</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">24013668</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>A</given-names></name><name><surname>Sanda</surname><given-names>T</given-names></name><name><surname>Grebliunaite</surname><given-names>R</given-names></name><name><surname>Carracedo</surname><given-names>A</given-names></name><name><surname>Salmena</surname><given-names>L</given-names></name><name><surname>Ahn</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High frequency of PTEN, PI3K, and AKT abnormalities in T-cell
acute lymphoblastic leukemia</article-title><source>Blood</source><year>2009</year><month>7</month><day>16</day><volume>114</volume><issue>3</issue><fpage>647</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">19458356</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>WL</given-names></name></person-group><article-title>Targeted therapy in T-cell malignancies: dysregulation of the
cellular signaling pathways</article-title><source>Leukemia</source><year>2010</year><month>1</month><volume>24</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">19865108</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>PS</given-names></name><name><surname>Whye</surname><given-names>DW</given-names></name><name><surname>Efimenko</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tosello</surname><given-names>V</given-names></name><name><surname>De Keersmaecker</surname><given-names>K</given-names></name><etal/></person-group><article-title>Targeting nonclassical oncogenes for therapy in
T-ALL</article-title><source>Cancer cell</source><year>2012</year><month>4</month><day>17</day><volume>21</volume><issue>4</issue><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">22516257</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>AJ</given-names></name><name><surname>Chan</surname><given-names>CS</given-names></name><name><surname>Dudgeon</surname><given-names>C</given-names></name><name><surname>Puzio-Kuter</surname><given-names>A</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name></person-group><article-title>The Evolution of Tumors in Mice and Humans with Germline p53
Mutations</article-title><source>Cold Spring Harb Symp Quant Biol</source><year>2015</year><month>12</month><day>7</day></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Georgopoulos</surname><given-names>K</given-names></name></person-group><article-title>Zinc finger-mediated protein interactions modulate Ikaros
activity, a molecular control of lymphocyte development</article-title><source>EMBO J</source><year>1996</year><month>10</month><day>1</day><volume>15</volume><issue>19</issue><fpage>5358</fpage><lpage>5369</lpage><pub-id pub-id-type="pmid">8895580</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>LA</given-names></name><name><surname>Ferrini</surname><given-names>R</given-names></name><name><surname>Cobb</surname><given-names>BS</given-names></name><name><surname>Weinmann</surname><given-names>AS</given-names></name><name><surname>Hahm</surname><given-names>K</given-names></name><name><surname>Ernst</surname><given-names>P</given-names></name><etal/></person-group><article-title>Down-regulation of TDT transcription in
CD4(+)CD8(+) thymocytes by Ikaros proteins in direct
competition with an Ets activator</article-title><source>Genes Dev</source><year>2001</year><month>7</month><day>15</day><volume>15</volume><issue>14</issue><fpage>1817</fpage><lpage>1832</lpage><pub-id pub-id-type="pmid">11459831</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottardi</surname><given-names>S</given-names></name><name><surname>Mavoungou</surname><given-names>L</given-names></name><name><surname>Bourgoin</surname><given-names>V</given-names></name><name><surname>Mashtalir</surname><given-names>N</given-names></name><name><surname>Affar el</surname><given-names>B</given-names></name><name><surname>Milot</surname><given-names>E</given-names></name></person-group><article-title>Direct protein interactions are responsible for Ikaros-GATA and
Ikaros-Cdk9 cooperativeness in hematopoietic cells</article-title><source>Molecular and cellular biology</source><year>2013</year><month>8</month><volume>33</volume><issue>16</issue><fpage>3064</fpage><lpage>3076</lpage><pub-id pub-id-type="pmid">23732910</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galy</surname><given-names>A</given-names></name><name><surname>Christopherson</surname><given-names>I</given-names></name><name><surname>Ferlazzo</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>Georgopoulos</surname><given-names>K</given-names></name></person-group><article-title>Distinct signals control the hematopoiesis of lymphoid-related
dendritic cells</article-title><source>Blood</source><year>2000</year><month>1</month><day>1</day><volume>95</volume><issue>1</issue><fpage>128</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">10607695</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>SN</given-names></name><name><surname>Jessup</surname><given-names>HK</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name></person-group><article-title>Enforced expression of the Ikaros isoform IK5 decreases the
numbers of extrathymic intraepithelial lymphocytes and natural killer
1.1+ T cells</article-title><source>Blood</source><year>2002</year><month>1</month><day>15</day><volume>99</volume><issue>2</issue><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">11781232</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronni</surname><given-names>T</given-names></name><name><surname>Payne</surname><given-names>KJ</given-names></name><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Bradley</surname><given-names>MN</given-names></name><name><surname>Dorsam</surname><given-names>G</given-names></name><name><surname>Dovat</surname><given-names>S</given-names></name></person-group><article-title>Human Ikaros function in activated T cells is regulated by
coordinated expression of its largest isoforms</article-title><source>J Biol Chem</source><year>2007</year><month>1</month><day>26</day><volume>282</volume><issue>4</issue><fpage>2538</fpage><lpage>2547</lpage><pub-id pub-id-type="pmid">17135265</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>AP</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Morris</surname><given-names>JPt</given-names></name><name><surname>Silverman</surname><given-names>LB</given-names></name><name><surname>Sanchez-Irizarry</surname><given-names>C</given-names></name><etal/></person-group><article-title>Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia</article-title><source>Science</source><year>2004</year><month>10</month><day>8</day><volume>306</volume><issue>5694</issue><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">15472075</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hales</surname><given-names>EC</given-names></name><name><surname>Taub</surname><given-names>JW</given-names></name><name><surname>Matherly</surname><given-names>LH</given-names></name></person-group><article-title>New insights into Notch1 regulation of the PI3K-AKT-mTOR1
signaling axis: targeted therapy of gamma-secretase inhibitor resistant
T-cell acute lymphoblastic leukemia</article-title><source>Cellular signalling</source><year>2014</year><month>1</month><volume>26</volume><issue>1</issue><fpage>149</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">24140475</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Decreased expression of miR-26b in <italic>Pten</italic>-knockout mouse T-ALL
cells and human T-ALL cells</title><p>A: miRNA profile of Array data. KO576, KO577, KO578 and KO579 are
<italic>Pten</italic>-knockout mouse T-ALL samples. WT580 and WT581 are
wild-type mouse thymocytes. B: Decreased miR-26b expression level in mouse Pten
deficient T-ALL cell lines (LPN248, LPN236 and LPN228) compared with mouse
<italic>Ink4a/Arf</italic> knock-out T-ALL cell line (LPN211) and mouse wild
type thymocytes (P&lt;0.001). C. Decreased miR-26b in human T-ALL cell lines,
CCRF-CEM, SUPT1, LOUCY, KOPT-K1, JURKAT and MOLT4 compared with postnatal normal
human thymus (P&lt;0.001). D: Decreased expression level of miR-26b in human
primary T-ALL samples (P&lt;0.001). E. Correlation of miR-26b expression level
with <italic>PTEN</italic> level in human primary T-ALL samples
(r=0.3987, P=0.039).</p></caption><graphic xlink:href="nihms855382f1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>miR-26b inhibits proliferation and promotes apoptosis in T-ALL cells
<italic>in vitro</italic></title><p>A: Exogenous miR-26b expression levels in T-ALL cell lines (*P&lt;0.05).
B: Expression of exogenous miR-26b significantly reduced the proliferation of
CCRF-CEM, KOPTK1, and MOLT4 cells (p&lt;0.05). C: Expression of exogenous
miR-26b significantly promoted apoptosis of CCRF-CEM, KOPT-K1, and MOLT4 cells
(p&lt;0.05). V: vector control.</p></caption><graphic xlink:href="nihms855382f2"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>miR-26b inhibits the growth of T-ALL cells <italic>in vivo</italic></title><p>A: Tumor burden was monitored and assessed in a xenograft T-ALL mouse model by
bioluminescence imaging at the indicated time points. B: Tumor burden of
peripheral blood was detected by flow cytometry (GFP and hCD45 staining) and the
phospho-AKT level of CCRF-CEM-FFluc cells was measured by intracellular staining
flow cytometry on day 15. C: Kaplan-Meier survival curve (P=0.0031).</p></caption><graphic xlink:href="nihms855382f3"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title><italic>PIK3CD</italic> is a miR-26b target gene</title><p>A: miR-26b binding site on wild-type <italic>PIK3CD</italic>-3&#8242;UTR and
mutant <italic>PIK3CD</italic>-3&#8242;UTR. <italic>PIK3CD</italic> mutant
indicated the artificially mutated nucleotides and remaining wild type
nucleotides of the 3&#8242;UTR of <italic>PIK3CD</italic>. B: Dual-luciferase
assay analysis for miR-26b binding site; miR-26b inhibited the activity of
luciferase containing wild-type 3&#8242;UTR (*P&lt;0.001) but not that
of luciferase containing mutant (mut) or null 3&#8242;UTR
(**P&gt;0.05, ***P&gt;0.05). C: Protein
levels of PIK3CD (p110&#948;), p-AKT and total AKT in T-ALL cells infected
with control vector and overexpressing miR-26b. p-AKT expression levels were
relatively decreased 25.6%, 22.6% and 22.6% in CCRF-CEM,
KOPT-K1 and MOLT4 cells, respectively, after miR-26b overexpression. V: vector
control.</p></caption><graphic xlink:href="nihms855382f4"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Inhibition of PIK3CD by CAL-101 or shRNAs reduced the growth of T-ALL
cells</title><p>A: T-ALL cell lines were treated with 1&#8211;40 &#956;M of CAL-101, and
cell inhibition ratios were measured at several time points. B: PI3K
p110&#948; protein levels were assessed by Western blot in T-ALL cells
infected with control vector or overexpressing shRNAs for
<italic>PIK3CD</italic>. C: In CCRF-CEM and KOPT-K1 T-ALL cell lines, cell
proliferation decreased and apoptosis increased after the knockdown of
<italic>PIK3CD</italic> by shRNA1 or shRNA2.</p></caption><graphic xlink:href="nihms855382f5"/></fig><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>PTEN induces miR-26b expression by altering the expression patterns of Ikaros
isoforms</title><p>A: In CCRF-CEM and MOLT4 cells, miR-26b levels were increased after PTEN
overexpression (P&lt;0.001 and P&lt;0.01, respectively). In KOPT-K1 cells, there
was no change in the miR-26b level (P&gt;0.05). B: miR-26b levels were decreased
after PTEN knocked-down by shRNAs in KOPT-K1 cells (P&lt;0.001). C: Expression
of Ikaros isoforms in normal bone marrow (1 and 2), normal thymocytes (1 and 2)
and T-ALL cell lines by Western blotting. D: miR-26b levels were elevated after
Ikaros dominant positive isoform IK1 overexpression in CCRF-CEM, MOLT4, and
KOPT-K1 T-ALL cells (P&lt;0.001). E: ChIP assay: Top panel indicates the
position detected by real-time quantitative PCR. Bottom panel: ChIP analysis of
CCRF-CEM cells with vector control, exogenous PTEN expression and IK1-Flag
overexpression. DNA immune-precipitated by Ikaros antibody, Flag-tag antibody or
immunoglobulin G (IgG negative control) was amplified by qPCR. The percentage of
Input was significantly elevated in exogenous PTEN expression and IK1-Flag
overexpression cells (*P&lt;0.05, **P&lt;0.005),
compared with the vector control. F: IK1 significantly activated firefly
luciferase expression by binding to the miR-26b promoter region on
co-transfected pGL3 plasmid in 293T cells compared with empty vector and the
Ikaros dominant negative isoform (IK-DN) (*P&lt;0.01,
**P&lt;0.05). IK-DN (from 10 ng to 100 ng) also significantly
decreased the luciferase activity of IK1 co-transfected with pGL3 plasmid
(P&lt;0.05). G. Effect of exogenous expression on IK-DP and IK-DN. There was
steady Ikaros dominant positive isoform iand decreased Ikaros dominant negative
isoform in CCRF-CEM and MOLT4 cells that have no endogenous PTEN expression.
There was no change in the Ikaros dominant negative isoform in KOPT-K1 T-ALL
cells, which have endogenous PTEN. H. Effect of knocking-down of PTEN on the
expression levels of IK-DP and IK-DN. After PTEN knocked-down by shRNAs in
KOPT-K1 cells, Ikaros-DN isoform was increased, but no changes of Ikaros-DP
isoform. V: vector control.</p></caption><graphic xlink:href="nihms855382f6"/></fig><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>miR-26b is involved in T-ALL pathogenesis as a tumor suppressor</title><p>miR-26b directly inhibits <italic>PIK3CD</italic> in the PI3K/AKT pathway and
indirectly inhibits the Notch pathway. Both pathways regulate T-ALL cell growth.
Tumor suppressor PTEN inhibits the PI3K pathway and alters the splice forms of
Ikaros, thus regulating the miR-26b expression level as one of its important
regulators in T-ALL.</p></caption><graphic xlink:href="nihms855382f7"/></fig></floats-group></article>